Published in J Clin Microbiol on November 17, 2010
Systematic review of the performance of HIV viral load technologies on plasma samples. PLoS One (2014) 1.06
Mechanisms and factors that influence high frequency retroviral recombination. Viruses (2011) 1.02
Cross-platform analysis of HIV-1 RNA data generated by a multicenter assay validation study with wide geographic representation. J Clin Microbiol (2012) 0.97
Large-scale analysis of the prevalence and geographic distribution of HIV-1 non-B variants in the United States. J Clin Microbiol (2013) 0.95
Pilot studies for development of an HIV subtype panel for surveillance of global diversity. AIDS Res Hum Retroviruses (2012) 0.95
Improving Clinical Laboratory Efficiency: Introduction of Systems for the Diagnosis and Monitoring of HIV Infection. Open Virol J (2012) 0.94
Quantification of viral loads lower than 50 copies per milliliter by use of the Cobas AmpliPrep/Cobas TaqMan HIV-1 test, version 2.0, can predict the likelihood of subsequent virological rebound to >50 copies per milliliter. J Clin Microbiol (2013) 0.89
Evaluation of the NucliSens EasyQ v2.0 assay in comparison with the Roche Amplicor v1.5 and the Roche CAP/CTM HIV-1 Test v2.0 in quantification of C-clade HIV-1 in plasma. PLoS One (2014) 0.85
Increasing HIV subtype diversity and its clinical implications in a sentinel North American population. Can J Infect Dis Med Microbiol (2013) 0.82
Upgraded Cobas Ampliprep-Cobas TaqMan version 2.0 HIV-1 RNA quantification assay versus first version: correction of underestimations. J Clin Microbiol (2011) 0.82
Clinical evaluation of a low cost, in-house developed real-time RT-PCR human immunodeficiency virus type 1 (HIV-1) quantitation assay for HIV-1 infected patients. PLoS One (2014) 0.81
Development and optimization of a real-time PCR assay for detection of herpes simplex and varicella-zoster viruses in skin and mucosal lesions by use of the BD Max open system. J Clin Microbiol (2014) 0.81
Past, present and future molecular diagnosis and characterization of human immunodeficiency virus infections. Emerg Microbes Infect (2012) 0.77
An avoidable transmission of HIV from mother to child. CMAJ (2010) 0.76
Development of an HIV-1 Subtype Panel in China: Isolation and Characterization of 30 HIV-1 Primary Strains Circulating in China. PLoS One (2015) 0.75
Analytical Performances of Human Immunodeficiency Virus Type 1 RNA-Based Amplix® Real-Time PCR Platform for HIV-1 RNA Quantification. AIDS Res Treat (2016) 0.75
Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis. AIDS (2016) 0.75
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 18.38
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med (2008) 8.19
HIV viral load markers in clinical practice. Nat Med (1996) 4.78
The challenge of HIV-1 subtype diversity. N Engl J Med (2008) 3.88
A new human immunodeficiency virus derived from gorillas. Nat Med (2009) 3.47
Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis (2009) 3.37
Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes. J Acquir Immune Defic Syndr (2007) 2.89
Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane Database Syst Rev (2009) 2.77
Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J Clin Microbiol (1999) 2.68
Subtype-specific problems with quantification of plasma HIV-1 RNA. AIDS (1997) 2.60
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis (2009) 1.89
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr (2009) 1.83
Erroneously low or undetectable plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic acid load, determined by polymerase chain reaction, in West African and American patients with non-B subtype HIV-1 infection. Clin Infect Dis (2001) 1.69
Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. Swiss HIV Cohort Study. J Acquir Immune Defic Syndr (2000) 1.69
Impact of HIV type 1 subtype variation on viral RNA quantitation. AIDS Res Hum Retroviruses (1999) 1.67
A RealTime HIV-1 viral load assay for automated quantitation of HIV-1 RNA in genetically diverse group M subtypes A-H, group O and group N samples. J Virol Methods (2007) 1.47
Failure to quantify viral load with two of the three commercial methods in a pregnant woman harboring an HIV type 1 subtype G strain. AIDS Res Hum Retroviruses (1998) 1.46
Evaluation of the Abbott m2000rt RealTime HIV-1 assay with manual sample preparation compared with the ROCHE COBAS AmpliPrep/AMPLICOR HIV-1 MONITOR v1.5 using specimens from East Africa. J Virol Methods (2009) 1.45
Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from Brazil. J Virol Methods (2006) 1.33
Performance of three commercial viral load assays, Versant human immunodeficiency virus type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, testing HIV-1 non-B subtypes and recombinant variants. J Clin Microbiol (2008) 1.32
Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. J Virol Methods (2006) 1.31
Clinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection--a quantitative review. PLoS One (2009) 1.31
Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from London: comparison to VERSANT HIV-1 RNA 3.0, AMPLICOR HIV-1 MONITOR v1.5, and LCx HIV RNA Quantitative assays. J Virol Methods (2006) 1.30
Impaired quantification of plasma HIV-1 RNA with a commercialized real-time PCR assay in a couple of HIV-1-infected individuals. J Clin Virol (2007) 1.27
Short communication: identification of a novel HIV type 1 subtype H/J recombinant in Canada with discordant HIV viral load (RNA) values in three different commercial assays. AIDS Res Hum Retroviruses (2007) 1.22
Comparison of the Generic HIV Viral Load assay with the Amplicor HIV-1 monitor v1.5 and Nuclisens HIV-1 EasyQ v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes: the Kesho Bora preparatory study. J Virol Methods (2009) 1.20
The five-year impact of an evolving global epidemic, changing migration patterns, and policy changes in a regional Canadian HIV population. Health Policy (2008) 1.09
Correlation between viral load measurements and outcome in clinical trials of antiviral drugs. AIDS (1995) 1.08
Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens. J Med Virol (2010) 1.08
Underevaluation of HIV-1 plasma viral load by a commercially available assay in a cluster of patients infected with HIV-1 A/G circulating recombinant form (CRF02). J Acquir Immune Defic Syndr (2002) 0.96
Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant forms. J Clin Microbiol (2003) 0.95
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Top HIV Med (2009) 0.93
Monitoring virologic responses to antiretroviral therapy in HIV-infected adults in Kenya: evaluation of a low-cost viral load assay. PLoS One (2009) 0.93
HIV update. Diagnostic tests and markers of disease progression and response to therapy. Am J Clin Pathol (2002) 0.90
The first B/G intersubtype recombinant form of human immunodeficiency virus type 1 (HIV-1) identified in Germany was undetected or underquantitated by some commercial viral load assays. J Med Virol (2006) 0.88
HIV-1 genetic diversity in antenatal cohort, Canada. Emerg Infect Dis (2005) 0.87
Comparative performance of the Amplicor HIV-1 Monitor Assay versus NucliSens EasyQ in HIV subtype C-infected patients. J Med Virol (2006) 0.86
Development and evaluation of HIV-1 subtype RNA panels for the standardization of HIV-1 NAT assays. J Virol Methods (2006) 0.86
Measurement of HIV RNA in patients infected by subtype C by assays optimized for subtype B results in an underestimation of the viral load. J Med Virol (2004) 0.85
The effect of raltegravir on the glucuronidation of lamotrigine. J Clin Pharmacol (2009) 0.84
Comparative quantification of diverse serotypes of HIV-1 in plasma from a diverse population of patients. J Med Virol (2000) 0.84
Comparison of three commercial assays for the quantification of plasma HIV-1 RNA from individuals with low viral loads. AIDS (1999) 0.81
Comparative evaluation of the COBAS AmpliPrep/COBAS TaqMan HIV type 1 test (CAP/CTM) and VERSANT HIV type 1 RNA 3.0 assay (bDNA) for quantifying HIV type 1 viral loads in China. AIDS Res Hum Retroviruses (2008) 0.81
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis (2005) 5.20
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet (2004) 3.59
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
Laboratory detection of Enterobacteriaceae that produce carbapenemases. J Clin Microbiol (2012) 2.24
The epidemiology of intensive care unit-acquired hyponatraemia and hypernatraemia in medical-surgical intensive care units. Crit Care (2008) 2.17
Neonatal exposure to active pulmonary tuberculosis in a health care professional. CMAJ (2005) 2.05
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis (2012) 2.00
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Severe group a streptococcal soft-tissue infections in Ontario: 1992-1996. Clin Infect Dis (2002) 1.93
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS (2009) 1.90
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med (2015) 1.86
The quality of reports of critical care meta-analyses in the Cochrane Database of Systematic Reviews: an independent appraisal. Crit Care Med (2007) 1.77
Characterization of intensive care unit acquired hyponatremia and hypernatremia following cardiac surgery. Can J Anaesth (2010) 1.77
Retention among North American HIV-infected persons in clinical care, 2000-2008. J Acquir Immune Defic Syndr (2013) 1.73
Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr (2013) 1.72
Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med (2006) 1.69
Clinical and epidemiologic features of group a streptococcal pneumonia in Ontario, Canada. Arch Intern Med (2003) 1.67
Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. AIDS (2011) 1.61
The NK receptor NKp30 mediates direct fungal recognition and killing and is diminished in NK cells from HIV-infected patients. Cell Host Microbe (2013) 1.59
Incidence, risk factors, and outcomes of Klebsiella pneumoniae bacteremia. Am J Med (2009) 1.56
Establishment and maintenance of vascular access in incident hemodialysis patients: a prospective cost analysis. J Am Soc Nephrol (2004) 1.53
HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol Clin (2008) 1.50
Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clin Infect Dis (2011) 1.50
Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology (2004) 1.49
Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol (2006) 1.49
Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med (2012) 1.47
The Direct Medical Costs of Late Presentation (<350/mm) of HIV Infection over a 15-Year Period. AIDS Res Treat (2011) 1.41
Outcome of ICU patients with Clostridium difficile infection. Crit Care (2012) 1.38
Virologic and immunologic response to HAART, by age and regimen class. AIDS (2010) 1.34
Epidemiology of severe trauma among status Aboriginal Canadians: a population-based study. CMAJ (2005) 1.34
Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa. Am J Trop Med Hyg (2005) 1.33
The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. CMAJ (2003) 1.30
Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. Sex Transm Infect (2012) 1.25
Short communication: identification of a novel HIV type 1 subtype H/J recombinant in Canada with discordant HIV viral load (RNA) values in three different commercial assays. AIDS Res Hum Retroviruses (2007) 1.22
Compartmentalization of the gut viral reservoir in HIV-1 infected patients. Retrovirology (2007) 1.19
Cytotoxic CD4+ T cells use granulysin to kill Cryptococcus neoformans, and activation of this pathway is defective in HIV patients. Blood (2006) 1.15
CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther (2010) 1.13
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. Int J Epidemiol (2012) 1.11
Evaluation of brief screening tools for neurocognitive impairment in HIV/AIDS: a systematic review of the literature. AIDS (2013) 1.10
The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study. BMC Infect Dis (2011) 1.09
Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One (2011) 1.09
Disparities in the quality of HIV care when using US Department of Health and Human Services indicators. Clin Infect Dis (2014) 1.06
HIV dementia patients exhibit reduced viral neutralization and increased envelope sequence diversity in blood and brain. AIDS (2002) 1.04
Evaluation of StrepB carrot broth versus Lim broth for detection of group B Streptococcus colonization status of near-term pregnant women. J Clin Microbiol (2008) 1.03
Incidence, risk factors, and outcomes of Fusobacterium species bacteremia. BMC Infect Dis (2013) 1.03
SOFA is superior to MOD score for the determination of non-neurologic organ dysfunction in patients with severe traumatic brain injury: a cohort study. Crit Care (2006) 1.03
Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS. J Neurol Sci (2011) 1.03
Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa. Can J Infect Dis Med Microbiol (2008) 1.02
Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS (2008) 1.02
The clinical implications of high rates of intimate partner violence against HIV-positive women. J Acquir Immune Defic Syndr (2013) 1.01
CD8+ T-cell response promotes evolution of hepatitis C virus nonstructural proteins. Gastroenterology (2011) 1.01
NeuroAIDS: an evolving epidemic. Can J Neurol Sci (2009) 1.01
HIV-1 viral diversity and its implications for viral load testing: review of current platforms. Int J Infect Dis (2011) 0.99
Outpatient parenteral antibiotic therapy: evolution of the Calgary adult home parenteral therapy program. Clin Invest Med (2002) 0.98
Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. AIDS Patient Care STDS (2003) 0.97
Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis (2013) 0.97
Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. J Acquir Immune Defic Syndr (2011) 0.97
Characterizing the HIV epidemic in the prairie provinces. Can J Infect Dis Med Microbiol (2012) 0.93
Dressing disruption is a major risk factor for catheter-related infections. Crit Care Med (2012) 0.93
Inflammation and epithelial cell injury in AIDS enteropathy: involvement of endoplasmic reticulum stress. FASEB J (2011) 0.91
Pill burden in HIV infection: 20 years of experience. Antivir Ther (2012) 0.91
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS (2008) 0.91
Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysis. PLoS One (2011) 0.91
Comparison of automated repetitive-sequence-based polymerase chain reaction and spa typing versus pulsed-field gel electrophoresis for molecular typing of methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis (2011) 0.90
HIV-related neurological syndromes reduce health-related quality of life. Can J Neurol Sci (2005) 0.90
Prevalence of USA300 colonization or infection and associated variables during an outbreak of community-associated methicillin-resistant Staphylococcus aureus in a marginalized urban population. Can J Infect Dis Med Microbiol (2007) 0.89
HIV and other lentiviral infections cause defects in neutrophil chemotaxis, recruitment, and cell structure: immunorestorative effects of granulocyte-macrophage colony-stimulating factor. J Immunol (2006) 0.89
Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionals. Can J Infect Dis Med Microbiol (2007) 0.88
Similar challenges with retention in care issues. Clin Infect Dis (2007) 0.88
Domestic violence screening: prevalence and outcomes in a Canadian HIV population. AIDS Patient Care STDS (2010) 0.87
Discrepancies in assignment of subtype/recombinant forms by genotyping programs for HIV type 1 drug resistance testing may falsely predict superinfection. AIDS Res Hum Retroviruses (2008) 0.87
Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. AIDS (2015) 0.87
External quality assessment of HLA-B*5701 reporting: an international multicentre survey. Antivir Ther (2007) 0.86
Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection. Retrovirology (2010) 0.85
Evaluation of the Xpert® group B streptococcus real-time polymerase chain reaction assay compared to StrepB Carrot Broth™ for the rapid intrapartum detection of group B streptococcus colonization. Diagn Microbiol Infect Dis (2011) 0.85
Growth hormone prevents human immunodeficiency virus-induced neuronal p53 expression. Ann Neurol (2003) 0.85
Adverse health effects for individuals who move between HIV care centers. J Acquir Immune Defic Syndr (2011) 0.84
The OPTICC trial: a multi-institutional study of occult pneumothoraces in critical care. Am J Surg (2009) 0.84
Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy. Ann Intern Med (2002) 0.83
High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults. HIV Clin Trials (2012) 0.83
Evidence for host-driven selection of the HIV type 1 vpr gene in vivo during HIV disease progression in a transfusion-acquired cohort. AIDS Res Hum Retroviruses (2005) 0.83
Participation in HIV research: the importance of clinic contact factors. AIDS Patient Care STDS (2008) 0.83
Role of viral evolutionary rate in HIV-1 disease progression in a linked cohort. Retrovirology (2005) 0.83
Intimate partner violence and HIV: a review. Curr HIV/AIDS Rep (2013) 0.83
Is intra-abdominal hypertension a missing factor that drives multiple organ dysfunction syndrome? Crit Care (2014) 0.83
Increasing HIV subtype diversity in Canadian-born patients living in Southern Alberta, Canada. J Acquir Immune Defic Syndr (2011) 0.83